Cellectis S.A.

NASDAQ:CLLS

Biotechnology

Healthcare
$1.03 -0.65%

-$0.02 today

Market cap
$103.75M
Beta
2.75
P/E (TTM)
-4.6
EPS (TTM)
-$0.67
52W Low $1.35High $5.48

Volume 0.01M

Average 0.04M

CLLS Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Cellectis S.A.NASDAQ: CLLS

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $4.55M rose 125.9% year over year, ahead of the +39.3% change in trailing-twelve-month cost of revenue. Sequentially, it rose 51.8% from the prior quarter. Over 3 fiscal years it compounded at +4.9% a year.

Context

  • Cost of revenue amounted to 13.4% of revenue in FY2025, down 8.7 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +125.9% holds above the trailing-twelve-month pace of +39.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.55M+51.8% QoQ
Last fiscal yearDec 2025
$9.8M+6.7% YoY
LTMMar 2026
$12.33M+39.3% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+125.9%——
1 year+6.7%——
3-year CAGR+4.9%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
9.8M USD
Year-over-year change
+6.7%
4-year CAGR
+51.8%

Cost of Revenue vs competitors

How CLLS compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +39.3% is the 3rd highest of 5, against a peer median of +30.9%.
  • Cost of revenue amounts to 18.1% of revenue for CLLS, versus a peer median of 33.6%.
CLLS Competitors
Cost of Revenue for CLLS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMRNAmarin Corporation plcLTM Mar 2026$102.11M USD-27.2%-9.9%47.5%
DBVTDBV Technologies S.A.LTM Mar 2026$13.12M USD+215.9%-4.5%—
CLLSCellectis S.A.LTM Mar 2026$12.33M USD+39.3%+4.9%18.1%
KRROKorro Bio, Inc.LTM Mar 2026$1.03M USD——26.8%
MREOMereo BioPharma Group plcLTM Mar 2026$1.03M USD-5.2%—205.7%
SLNSilence Therapeutics plcLTM Mar 2026$309.37K USD—-73.0%33.6%
ANROAlto Neuroscience, Inc.LTM Mar 2026$284K USD+67.1%+24.6%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$66.6K USD———
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$0 USD—+8.0%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$0 USD———
ACIUAC Immune S.A.LTM Mar 2026CHF 0 CHF——0.0%
Peer median (excluding CLLS) —+30.9%-4.5%33.6%

Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.35M19.17M755K41.51M72.95M
Cost of Revenue1.84M8.48M7.42M9.18M9.8M
Gross Profit28.5M10.69M(6.66M)32.32M63.15M
Gross Margin93.9%55.7%-882.6%77.9%86.6%
Research & Development117.84M97.5M87.65M90.54M93.52M
Selling, General & Admin22.88M8.9M8.12M8.42M8.6M
Operating Expenses131.98M100.35M90.64M91.88M96.23M
Depreciation & Amortization14.16M18.44M18.52M19.85M20.06M
EBITDA(78.43M)(76.38M)(92.64M)(9.46M)(39.85M)
EBITDA Margin-258.4%-398.4%-12269.8%-22.8%-54.6%
Operating Income(103.48M)(89.67M)(97.3M)(59.55M)(33.08M)
Operating Margin-341.0%-467.7%-12887.7%-143.5%-45.3%
Interest Income719K1.12M3.61M11.28M9.5M
Interest Expense4.37M3.79M5.31M7.45M8.11M
Other Income / Expenses6.73M(8.94M)(19.16M)22.79M(34.94M)
Income Before Tax(96.75M)(98.6M)(116.46M)(36.76M)(68.02M)
Pre-Tax Margin-318.8%-514.3%-15425.7%-88.6%-93.2%
Income Tax Expense(3K)87K371K0(423K)
Net Income(114.2M)(106.14M)(101.06M)(36.76M)(67.59M)
Net Margin-376.3%-553.6%-13385.3%-88.6%-92.7%
EPS (Basic)(1.93)(2.33)(1.77)(0.41)(0.68)
EPS (Diluted)(1.93)(2.33)(1.77)(0.41)(0.68)
Weighted Avg Shares44.82M45.55M57.01M90.57M100.28M
Weighted Avg Shares (Diluted)44.82M45.55M57.01M90.57M100.28M

Cellectis S.A.

NASDAQ:CLLS

Intrinsic Alpha fair value

Locked

Current Price

$1.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.